Latest Articles
Why Menstrual Blood May Be 'Goldmine' for Personalized Medicine — From Endometriosis to Diabetes and Cancer - StudyFinds
Why Menstrual Blood May Be 'Goldmine' for Personalized Medicine — From Endometriosis to Diabetes and Cancer StudyFinds
Published: April 9, 2025, 12:39 p.m.
Menstrual blood is being used to research a range of health conditions — from endometriosis to diabetes and cancer - The Conversation
Menstrual blood is being used to research a range of health conditions — from endometriosis to diabetes and cancer The Conversation
Published: April 9, 2025, 11:36 a.m.
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" - BioSpace
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" BioSpace
Published: April 8, 2025, 8:04 p.m.
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" - Yahoo
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" Yahoo
Published: April 8, 2025, 2:12 p.m.
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" - Business Wire
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" Business Wire
Published: April 8, 2025, 2:12 p.m.
Clinical Trial Participation Gaps in Endometrial Cancer - Physician's Weekly
Clinical Trial Participation Gaps in Endometrial Cancer Physician's Weekly
Published: April 8, 2025, 1:53 p.m.
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer - OncLive
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer OncLive
Published: April 8, 2025, 1:11 p.m.
Neoadjuvant Nivolumab Appears Effective for Resectable, dMMR Endometrial Cancer - Oncology Nurse Advisor
Neoadjuvant Nivolumab Appears Effective for Resectable, dMMR Endometrial Cancer Oncology Nurse Advisor
Published: April 8, 2025, 4 a.m.
Comorbidities in Midlife Tied to Cancer Risk - MedPage Today
Comorbidities in Midlife Tied to Cancer Risk MedPage Today
Published: April 7, 2025, 9:45 p.m.
Cancer Drug Pioneer Who Led Multiple FDA Approvals Takes CMO Role at Acrivon - Stock Titan
Cancer Drug Pioneer Who Led Multiple FDA Approvals Takes CMO Role at Acrivon Stock Titan
Published: April 7, 2025, 8:05 p.m.
Link copied to clipboard!